Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pediatric Graves’ disease

decisions regarding therapy

Okawa, Erin R.a; Grant, Frederick D.a,b; Smith, Jessica R.a

doi: 10.1097/MOP.0000000000000241
ADOLESCENT MEDICINE: Edited by Sara F. Forman Sarah Pitts

Purpose of review Graves’ disease is the most common cause of hyperthyroidism in the pediatric population. It occurs more often in adolescence and in girls; however, prepubertal children tend to have more severe disease, require longer medical therapy, and have a lower rate of remission as compared with pubertal children. The choice of which of the three therapeutic options to use (medical therapy, radioactive iodine ablation, or surgery) must be individualized. This update will focus on the current diagnostic and treatment modalities available, as well as address the controversy that exists with regards to permanent therapy.

Recent findings The diagnosis of Graves’ disease is often made clinically. With the development of second-generation and third-generation thyroid-stimulating hormone receptor antibody assays, it can be more reliably confirmed. An improved understanding of the underlying autoimmune process and genetics is underway; however, remission rates in children and adolescents remain low. Because of its ease of administration and long-term follow-up, there is a trend towards permanent therapy with radioactive iodine ablation when remission cannot be achieved with medical therapy.

Summary New genes and susceptibility loci have been identified with the hope of better understanding the refractory nature of Graves’ disease. Despite the low rates of remission, permanent therapy with radioactive iodine remains a good option.

aDivision of Endocrinology, Department of Medicine

bDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Boston Children's Hospital, Boston, Massachusetts, USA

Correspondence to Jessica R. Smith, MD, Division of Endocrinology, Department of Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. Tel: +1 617 355 0590; e-mail:

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.